Centaurus Financial’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.87M Buy
23,928
+754
+3% +$51.4K 0.07% 267
2026
Q1
$1.5M Buy
23,174
+694
+3% +$48.9K 0.07% 256
2025
Q4
$1.51M Buy
22,480
+187
+0.8% +$12.6K 0.07% 249
2025
Q3
$1.64M Buy
22,293
+135
+0.6% +$8.97K 0.08% 233
2025
Q2
$1.15M Sell
22,158
-157
-0.7% -$8.93K 0.07% 268
2025
Q1
$1.42M Buy
+22,315
New +$1.3M 0.09% 212
2024
Q4
Sell
-2,219
Closed -$127K 889
2024
Q3
$127K Buy
+2,219
New +$127K 0.01% 772
2018
Q3
Sell
-610
Closed -$10K 1166
2018
Q2
$10K Buy
+610
New +$11.5K ﹤0.01% 1549

Other funds holding HALO

Centaurus Financial's HALO Position: Q2 2026 in Review

Centaurus Financial increased its Halozyme (HALO) stake by 3.3% in Q2 2026, buying an estimated $51.4K and bringing the position to 23,928 shares worth $1.87M. The position accounts for 0.07% of the portfolio, ranked #267.

Centaurus Financial first reported a position in HALO in Q2 2018 and has held it in 8 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Centaurus Financial held 23,928 shares of Halozyme worth $1.87M as of Q2 2026.
  • Centaurus Financial bought 754 Halozyme shares in Q2 2026, an estimated $51.4K.
  • Halozyme made up 0.07% of Centaurus Financial's portfolio in Q2 2026, its #267 holding.
  • Centaurus Financial first reported a position in Halozyme in Q2 2018 and has held it in 8 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.